Adamis Pharma (ADMP) is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of allergy and respiratory disease.  The company’s current specialty pharmaceutical product candidates include; the Epinephrine Injection PFS syringe product for use in the emergency treatment of anaphylaxis; APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease; and APC-2000 for the treatment of bronchospasms. The company’s wholly owned subsidiary, U.S. Compounding, is a 503B drug outsourcing facility that provides prescription medications to patients, physician clinics, hospitals and surgery centers throughout most of the United States. For more information, visit the company’s website at www.adamispharmaceuticals.com